The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
2-(7-(2-(4-(2-hydroxypropan-2-yl)piperidin-1-yl)ethoxy)-9H-thioxanthen-4-yl)-6-morpholino-4H-pyran-4-one ID: ALA4791332
PubChem CID: 162671179
Max Phase: Preclinical
Molecular Formula: C32H38N2O5S
Molecular Weight: 562.73
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: CC(C)(O)C1CCN(CCOc2ccc3c(c2)Cc2cccc(-c4cc(=O)cc(N5CCOCC5)o4)c2S3)CC1
Standard InChI: InChI=1S/C32H38N2O5S/c1-32(2,36)24-8-10-33(11-9-24)12-17-38-26-6-7-29-23(19-26)18-22-4-3-5-27(31(22)40-29)28-20-25(35)21-30(39-28)34-13-15-37-16-14-34/h3-7,19-21,24,36H,8-18H2,1-2H3
Standard InChI Key: CVCGZRHVSJZEIE-UHFFFAOYSA-N
Molfile:
RDKit 2D
40 45 0 0 0 0 0 0 0 0999 V2000
14.9158 -13.0916 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.1275 -12.8811 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.3394 -13.6690 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.1683 -5.9539 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.4579 -5.5434 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.7501 -5.9542 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.7526 -6.7714 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.4630 -7.1778 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.1667 -6.7711 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
7.0438 -5.5479 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
8.4666 -9.6294 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
9.1744 -9.2227 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.1718 -8.4055 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.4614 -7.9950 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
7.7578 -8.4058 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.7562 -9.2230 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.9963 -5.9450 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.2901 -5.5387 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.2875 -4.7215 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.5813 -4.3151 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.8735 -4.7259 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.8761 -5.5431 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.5823 -5.9495 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.5849 -6.7667 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
11.2911 -7.1730 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.2937 -7.9902 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.0040 -8.3966 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.7118 -7.9899 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.7093 -7.1727 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.9989 -6.7622 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.4181 -8.3963 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
13.4206 -9.2135 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.1269 -9.6199 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.1294 -10.4370 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
13.4234 -10.8429 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.4240 -11.6566 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.1312 -12.0668 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.8394 -11.6572 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.8405 -10.8374 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.4227 -13.2921 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
2 1 1 0
3 2 1 0
4 5 2 0
5 6 1 0
6 7 1 0
7 8 2 0
8 9 1 0
4 9 1 0
6 10 2 0
11 12 1 0
12 13 1 0
13 14 1 0
14 15 1 0
15 16 1 0
11 16 1 0
8 14 1 0
17 18 1 0
18 19 1 0
19 20 2 0
20 21 1 0
21 22 2 0
22 23 1 0
18 23 2 0
23 24 1 0
24 25 1 0
25 26 1 0
26 27 2 0
27 28 1 0
28 29 2 0
29 30 1 0
25 30 2 0
17 30 1 0
32 33 1 0
31 32 1 0
33 34 1 0
28 31 1 0
4 22 1 0
34 35 1 0
34 39 1 0
35 36 1 0
36 37 1 0
37 38 1 0
38 39 1 0
37 2 1 0
2 40 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 562.73Molecular Weight (Monoisotopic): 562.2501AlogP: 5.06#Rotatable Bonds: 7Polar Surface Area: 75.38Molecular Species: BASEHBA: 8HBD: 1#RO5 Violations: 2HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): 2CX Acidic pKa: ┄CX Basic pKa: 8.60CX LogP: 4.63CX LogD: 3.41Aromatic Rings: 3Heavy Atoms: 40QED Weighted: 0.34Np Likeness Score: -0.40
References 1. Toledo-Sherman L,Breccia P,Cachope R,Bate JR,Angulo-Herrera I,Wishart G,Matthews KL,Martin SL,Cox HC,McAllister G,Penrose SD,Vater H,Esmieu W,Van de Poël A,Van de Bospoort R,Strijbosch A,Lamers M,Leonard P,Jarvis RE,Blackaby W,Barnes K,Eznarriaga M,Dowler S,Smith GD,Fischer DF,Lazari O,Yates D,Rose M,Jang SW,Muñoz-Sanjuan I,Dominguez C. (2019) Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models., 62 (6): [PMID:30840447 ] [10.1021/acs.jmedchem.8b01819 ]